Conference Coverage (Hepatitis)

Therapeutic Vaccines Offer Promise for Chronic HBV

Published in Hepatitis Weekly, February 17th, 1997

Two therapeutic vaccines for the treatment of chronic hepatitis B virus have been shown to be safe for use in humans, paving the way for future efficacy studies.

In a study conducted by the manufacturer, SmithKline Beecham Biologicals (Rixensart, Belgium), the vaccines elicited mild local adverse effects in the majority of patients and general flu-like symptoms in just under one-third of the study's 20 subjects.

These findings were presented by M. Wettendorff at the International Business Communications' conference, "Hepatitis: Latest Therapeutic Developments for Hepatitis B and C," held January 30-31, 1997 in Washington D.C.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1997-02-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry